Lights and shades of front-line treatment with covalent BTK inhibitors combined with venetoclax in patients with chronic lymphocytic leukemia. [PDF]
Oncol RevVisentin A, Mauro FR.
europepmc +1 more source
Bing-Neel syndrome: a case series of 46 patients from the United Kingdom. [PDF]
Blood AdvTomkins O +10 more
europepmc +1 more source
Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors. [PDF]
Blood ResHur JY +10 more
europepmc +1 more source
Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis. [PDF]
Adv TherDeng L +16 more
europepmc +1 more source
Orelabrutinib plus reduced-dose whole brain radiotherapy in elderly primary central nervous system lymphoma: a case report. [PDF]
Front OncolWang Q +5 more
europepmc +1 more source
Renal Lymphocytic Invasion in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Leading to Acute Kidney Injury: A Case Report [PDF]
Byrnes, Catherine +5 more
core +1 more source
Related searches:
Zanubrutinib (Brukinsa®), an orally-administered Bruton tyrosine kinase (BTK) inhibitor, is being developed by BeiGene for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, based
openaire +2 more sources